facebook
Subscribe50$/product give away!


Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE solution/ drops


  1. Description
  2. Clinical Pharmacology
  3. Indications And Usage
  4. Contraindications
  5. Warnings Not For Injection- For Topical Ophthalmic Use Only.
  6. Precautions
  7. Adverse Reactions
  8. Dosage And Administration
  9. How Supplied
  10. Package/label Principal Display Panel

Description 

Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution USP, 0.25%/0.4% is a disclosing agent with rapid anesthetic action and short duration.

Fluorescein sodium is represented by the following structural formula:

Fluorescein Sodium Structural Formula

C20H10Na2O5
Mol. Wt. 376.28

Chemical Name: Spiro (isobenzofuran-1 (3H),9'-(9H) xanthene)-3-one, 3',6' dihydroxy-, disodium salt.

Benoxinate hydrochloride is represented by the following structural formula:

Benzoxinate Sodium Structural Formula

C17H28N2O3 HCl
Mol. Wt. 344.88

Chemical Name: 2-(Diethylamino) ethyl 4-amino-3-butoxybenzoate monohydrochloride.

Each mL Contains: ACTIVES: Fluorescein Sodium 2.5 mg (0.25%), Benoxinate Hydrochloride 4 mg (0.4%); INACTIVES: Boric Acid, Povidone, Purified Water. Hydrochloric Acid may be added to adjust pH (4.3 5.3). PRESERVATIVE ADDED: Chlorobutanol 1%.

Clinical Pharmacology 

Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution USP, 0.25%/0.4% is the combination of a disclosing agent with a rapidly acting anesthetic of short duration.

Indications And Usage 

For procedures requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent such as tonometry, gonioscopy, removal of corneal foreign bodies and other short corneal or conjunctival procedures.

Contraindications 

Known hypersensitivity to any component of this product.

Warnings Not For Injection- For Topical Ophthalmic Use Only. 

Prolonged use of a topical ocular anesthetic is not recommended. It may produce permanent corneal opacification with accompanying visual loss.

Precautions 

Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution USP, 0.25%/0.4% should be used cautiously and sparingly in patients with known allergies, cardiac disease, or hyperthyroidism. The long-term toxicity is unknown; prolonged use may possibly delay wound healing. Although exceedingly rare with ophthalmic application of local anesthetics, it should be borne in mind that systemic toxicity manifested by central nervous system stimulation followed by depression may occur. Protection of the eye from irritation chemicals, foreign bodies and rubbing during the period of anesthesia is very important. Tonometers soaked in sterilizing or detergent solutions should be thoroughly rinsed with sterile distilled water prior to use. Patients should be advised to avoid touching the eye until the anesthesia has worn off.

Pregnancy

Pregnancy Category C. Animal reproduction studies have not been conducted with Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution USP, 0.25%/0.4%. It is also not known whether Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution USP, 0.25%/0.4% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution USP, 0.25%/0.4% should be given to a pregnant woman only if clearly needed.

Nursing Mothers

Caution should be exercised when Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution USP, 0.25%/0.4% is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Adverse Reactions 

Occasional temporary stinging, burning, and conjunctival redness have been reported after use of ocular anesthetics, as well as a rare, severe, immediate-type, apparent hyper-allergic corneal reaction, with acute, intense and diffuse epithelial keratitis, a gray, ground glass appearance, sloughing of large areas of necrotic epithelium, corneal filaments and sometimes, iritis with descemetitis.

Allergic contact dermatitis with drying and fissuring of the fingertips has been reported

Dosage And Administration 

Usual Dosage: Removal of foreign bodies and sutures, and for tonometry, 1 to 2 drops (in single instillations) in each eye before operating.

How Supplied 

Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution USP, 0.25%/0.4% is supplied in a glass bottle with a sterilized dropper in the following size:

5 mL NDC 24208-732-05

Storage:

Store in a refrigerator at 2 -8 C (36 -46 F).

User may store at room temperature up to one month.

Keep tightly closed.

DO NOT USE IF IMPRINTED BODY SEAL IS NOT INTACT.

KEEP OUT OF REACH OF CHILDREN.

Revised: November 2012

Bausch & Lomb Incorporated
Tampa, FL 33637
Bausch & Lomb Incorporated

9117602 (Folded)

9117702 (Flat)

Prod. No. 30107

Package/label Principal Display Panel 

Fluorescein Sodium and Benox Hydrochloride Image

NDC 24208-732-05

BAUSCH + LOMB

Fluorescein Sodium and

Benoxinate Hydrochloride

Ophthalmic Solution USP,

0.25%/0.4%

(Sterile)

(with Sterilized Dropper)

5 mL

Rx only

9115101

AB30107

FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE
fluorescein sodium and benoxinate hydrochloride solution/ drops
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:24208-732
Route of Administration OPHTHALMIC
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
BENOXINATE HYDROCHLORIDE (UNII: 0VE4U49K15) (BENOXINATE - UNII:AXQ0JYM303) BENOXINATE HYDROCHLORIDE 4 mg in 1 mL
FLUORESCEIN SODIUM (UNII: 93X55PE38X) (FLUORESCEIN - UNII:TPY09G7XIR) FLUORESCEIN SODIUM 2.5 mg in 1 mL
Inactive Ingredients
Ingredient Name Strength
BORIC ACID (UNII: R57ZHV85D4)
POVIDONES (UNII: FZ989GH94E)
WATER (UNII: 059QF0KO0R)
HYDROCHLORIC ACID (UNII: QTT17582CB)
CHLOROBUTANOL (UNII: HM4YQM8WRC)
Packaging
# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:24208-732-05 1 in 1 CARTON
1 5 mL in 1 BOTTLE, GLASS; Type 0: Not a Combination Product
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
Unapproved drug other 01/01/1995
Labeler - Bausch & Lomb Incorporated (196603781)
Establishment
Name Address ID/FEI Business Operations
Bausch & Lomb Incorporated 079587625 MANUFACTURE(24208-732)

Revised: 11/2012 Bausch & Lomb Incorporated



Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources
2017 © Copyright PharmacyHQ.com. Questions?
Please contact: pharmacyhq.mail@gmail.com